208 related articles for article (PubMed ID: 38022580)
21. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
22. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma.
Park YP; Jin L; Bennett KB; Wang D; Fredenburg KM; Tseng JE; Chang LJ; Huang J; Chan EKL
Oral Oncol; 2018 Mar; 78():145-150. PubMed ID: 29496042
[TBL] [Abstract][Full Text] [Related]
23. Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.
Karvouni M; Vidal-Manrique M; Susek KH; Hussain A; Gilljam M; Zhang Y; Gray JD; Lund J; Kaufmann G; Ljunggren HG; Ji H; Lundqvist A; Wagner AK; Guo W; Alici E
Cytotherapy; 2023 Jul; 25(7):763-772. PubMed ID: 37055320
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
[TBL] [Abstract][Full Text] [Related]
25. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
26. Impaired intratumoral natural killer cell function in head and neck carcinoma.
Mele D; Pessino G; Trisolini G; Luchena A; Benazzo M; Morbini P; Mantovani S; Oliviero B; Mondelli MU; Varchetta S
Front Immunol; 2022; 13():997806. PubMed ID: 36341402
[TBL] [Abstract][Full Text] [Related]
27. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of HLA-B-associated transcript 3 impairs the tumoricidal effect of natural killer cells through promoting the T cell immunoglobulin and mucin domain-containing-3 signaling in a mouse head and neck squamous cell carcinoma model.
Yang J; Xiang J; Zhu M; Zhao Y; Zhou L; Hu B; Wang C
Immunobiology; 2022 Jan; 227(1):152127. PubMed ID: 34968777
[TBL] [Abstract][Full Text] [Related]
29. Bitter Melon Enhances Natural Killer-Mediated Toxicity against Head and Neck Cancer Cells.
Bhattacharya S; Muhammad N; Steele R; Kornbluth J; Ray RB
Cancer Prev Res (Phila); 2017 Jun; 10(6):337-344. PubMed ID: 28465362
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
31. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.
Hu C; Liu M; Li Y; Zhao Y; Sharma A; Liu H; Schmidt-Wolf IGH
Front Immunol; 2023; 14():1213716. PubMed ID: 37457699
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
Hu Y; Tian ZG; Zhang C
Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
[TBL] [Abstract][Full Text] [Related]
33. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
34. CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma.
Liu T; Dai X; Xu Y; Guan T; Hong L; Zaib T; Zhou Q; Cheng K; Zhou X; Ma C; Sun P
J Transl Med; 2023 Oct; 21(1):710. PubMed ID: 37817249
[TBL] [Abstract][Full Text] [Related]
35. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.
Leuci V; Casucci GM; Grignani G; Rotolo R; Rossotti U; Vigna E; Gammaitoni L; Mesiano G; Fiorino E; Donini C; Pisacane A; Ambrosio LD; Pignochino Y; Aglietta M; Bondanza A; Sangiolo D
Oncoimmunology; 2018; 7(5):e1423167. PubMed ID: 29721373
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
37. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
38. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
[TBL] [Abstract][Full Text] [Related]
39. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
[No Abstract] [Full Text] [Related]
40. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
Yang N; Zhang C; Zhang Y; Fan Y; Zhang J; Lin X; Guo T; Gu Y; Wu J; Gao J; Zhao X; He Z
J Transl Med; 2024 Mar; 22(1):274. PubMed ID: 38475814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
